Beta Drugs Limited — Important, 06-11-2024: Financial Result Updates

Beta Drugs Limited reported a 28% increase in consolidated revenues for the first half of FY25, totaling ₹180.3 crores, driven by a 14% rise in exports and a 26% increase in Own Brand sales. Gross margins improved to 42.35%, and net profit rose by 23% to ₹24.44 crores. Management anticipates better performance in the second half, projecting revenues of ₹370-380 crores and EBITDA margins between 22-23%. The company continues to focus on productivity enhancements and new markets.